all report title image
  • Published On : Aug 2022
  • Code : CMI2217
  • Industry : Biotechnology
  • Pages : 175
  • Formats :

Tissue engineering is an interdisciplinary field addressed to develop functional three-dimensional tissues combining cells, scaffolds, and bioactive molecules. This field involves scientific areas such as cell biology, chemistry, material science, molecular biology, medicine, and engineering. It can be used to develop functional constructs that can be used to reestablish, maintain or improve the condition of injured body parts or tissues. Tissue engineering also assist in regeneration of damaged tissues by combining cells from the body with highly porous scaffold biomaterials. Scaffold biomaterials act as templates for tissue regeneration and guide the growth of new tissue.

Global tissue engineering market is estimated to be valued at US$ 9,436.0 million in 2022 and is expected to exhibit a CAGR of 11.7% during the forecast period (2022-2030).

Figure 1. Global Tissue Engineering Market Share (%), by Material Type, 2022

Tissue Engineering  | Coherent Market Insights

Increasing prevalence of kidney related disorders is expected to drive growth of the tissue engineering market

Tissue engineering is gaining traction in various areas such as wound care, burn treatment, orthopedics, neurology, urological products, and others. Tissue engineering can play an important role in the management of pediatric patients. Tissue or organs absent at the time of birth, in congenital anomalies such as bladder exstrophy, esophageal atresia, and congenital diaphragmatic hernia pose a serious challenges in surgical repair. Moreover, tissue engineering approaches have become a significant area of ​​interest in burn wound management. Tissue engineered skin substitutes have great potential for widespread applications in wound healing, particularly to address the limited availability of autologous skin increasing burn and trauma related injuries are expected to drive the global tissue engineering market growth. For instance, in Feb 2022, according to American Chemical Society, prevalence of chronic kidney disease (CKD) in the general population is estimated to be as high as 14% across the globe.

CMI table icon

Tissue Engineering Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 9,463.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 11.7% 2030 Value Projection: US$ 22,908.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Material Type: Synthetic, Biological, Others
  • By Application: Dermal, Orthopedic, Dental, Neurology, Others
Companies covered :

Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet.

Growth Drivers:
  • Increasing prevalence of kidney related disorders
  • Increasing ageing population and chronic diseases on the rise, there is a need for more effective medical treatments and henceforth a need for trained tissue engineering researchers
Restraints & Challenges:
  • High cost associated with tissue engineering treatment

Figure 2. Global Tissue Engineering Market Share (%), by Region, 2022

Tissue Engineering  | Coherent Market Insights

Increasing ageing population and chronic diseases on the rise, there is a need for more effective medical treatments and therefore a need for trained tissue engineering researchers are expected to drive market growth during the forecast period.

With an ageing population and chronic diseases on the rise, there is a need for more effective medical treatments and therefore a need for trained tissue engineering researchers to deliver these technologies. This is one of the major factor that is expected to drive the growth of the market. Tissue engineering offers alternatives to surgical reconstruction, transplantation, and directing mechanical devices to repair damaged tissues. For instance, in March 2020, according to National Library of Medicine, Spinal cord injury (SCI) affects an estimated three million persons worldwide, with ∼180,000 new cases reported each year leading to severe motor and sensory functional impairments that affect personal and social behaviors. As tissue engineering technology is being developed for use in a variety of different fields, particularly in the biomedical field, a clear understanding of the mechanisms of tissue engineering is important.

Global Tissue Engineering Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.

However, the COVID-19 pandemic had a positive impact on the global tissue engineering market, owing to increasing damages of organs due to COVID-19 and rising number of applications of tissue engineering as Tissue engineering (TE) strategies can be used to treat the damage with their interdisciplinary approaches. Tissue engineers could design drug delivery systems, scaffolds, and particularly biomaterials for the damaged tissues and organs. The key players in market were focused on developing and receiving approvals for new technologies such as 3D printing.

Global Tissue Engineering Market: Key Developments

In April 2022, Organogenesis Inc, a global leader in regenerative medicine, announced that the latest advanced wound care research on its PuraPly AM, Affinity, Apligraf, NuShield, Novachor, and Organogenesis Physician Solutions product lines would be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference, held between April 6 and April 10, 2022, in Phoenix, Arizona.

In May 2021, 3D Systems, leading provider of 3D printing announced the acquisition of Allevi, Inc., is a technology company making 3 dimensional bioprinters and bioinks to expand regenerative medicine initiative by accelerating growth in medical and pharmaceutical research laboratories.

In May 2021, 3D Systems, leading provider of 3D printing announced the acquisition of German software firm, Additive Works GmbH to expand simulation capabilities for rapid optimization of industrial-scale 3D printing processes.

Global Tissue Engineering Market: Restraint

Currently available tissue engineering methods face several problems, including ineffective cell growth, insufficient and unstable production of growth factors to stimulate cell communication and proper response, and lack of appropriate biomaterials and techniques to capture appropriate physiological architectures. Furthermore, the inability to control cellular functions and their various properties (biological, mechanical, electrochemical, and others) and problems of biomolecular detection and biosensors are other limitations associated with tissue engineering.

Furthermore, despite the growing interest in tissue engineering research, progress and high cost associated with the treatment is hampering the growth of the market.

Key Players

Major players operating in the global tissue engineering market include Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet.

Tissue engineering is a scientific field majorly focused on the development of tissue and organ substitutes by controlling biophysical, biological, and/or biomechanical parameters in the laboratory. Tissue engineering has emerged as a rapidly expanding approach to address shortage of organs in transplantation procedures and is a major component of regenerative medicine. The general principles of tissue engineering involve combining living cells with a synthetic or natural support or scaffold to build a three dimensional living construct that is structurally, functionally, and mechanically equal to or better than the tissue that is to be replaced. The primary goal of tissue engineering is to activate the body's lost regenerative abilities and, if necessary, to replace damaged tissue with tissue implants. Due to the particular technical difficulties, the generation of tissue constructs requires particularly close collaboration by physicians, cell biologists, materials scientists and engineers. The main goal of tissue engineering is the development of functional substitutes for damaged tissue. It is estimated that the majority of tissue engineering products are used to treat injuries and congenital defects, while tissue engineering products are less commonly used to treat disease.

Market Dynamics

Increasing adoption of inorganic growth strategies by key players in market such as acquisitions is expected to drive market growth over the forecast period. For instance, in October 2021 3D Systems, an engineering company provides comprehensive products and services, including 3D printers, print materials, software, on-demand manufacturing services, announced the acquisition of Volumetric Biotechnologies, a Houston-based biotech company. Volumetric’s mission is to develop the ability to manufacture human organs using bioprinting methods.  Through this acquisition, 3D Systems plans to establish a world-class research capability in Houston, Texas, related to life sciences.

Key features of the study:

  • This report provides an in-depth analysis of the global tissue engineering market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global tissue engineering market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global tissue engineering market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tissue engineering market

Detailed Segmentation:

  • Global Tissue Engineering Market, By Material Type:
    • Synthetic
    • Biological
    • Others
  • Global Tissue Engineering Market, By Application:
    • Dermal
    • Orthopedic
    • Dental
    • Neurology
    • Others
  • Global Tissue Engineering Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Acelity L.P. Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Allergan Plc
    • Athersys, Inc.
    • Braun
    • BioMimetic Therapeutics
    • Bio Tissue Technologies
    • R. Bard
    • International Stem Cell
    • Integra Lifesciences
    • Medtronic
    • Organogenesis Inc.
    • Osiris Therapeutics
    • RTI surgical, Inc.
    • Stryker Corporation
    • Tissue Regenix Group Plc.
    • Zimmer Biomet.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global tissue engineering market size is estimated to be valued at US$ 9.436.0 million in 2022 and is expected to exhibit a CAGR of 11.7% between 2022 and 2030.
Factors such as Increasing prevalence of kidney related disorders and increasing ageing population and chronic diseases on the rise, there is a need for more effective medical treatments and therefore a need for trained tissue engineering researchers are expected to drive the market growth.
Dermal is the leading application segment in the market.
The major factors hampering growth of the market include high cost associated with tissue engineering treatment.
Major players operating in the market Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo